Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris
NCT ID: NCT02100527
Last Updated: 2014-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2014-04-30
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Learn About the Study Medicine Called PF-07905428 in Healthy Participants and Participants With Acne Vulgaris
NCT06671834
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
NCT00666900
Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
NCT02998671
Apremilast in the Treatment of Moderate to Severe Acne
NCT01074502
Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne Vulgaris
NCT01628549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-05175157
PF-05175157
200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
Placebo
Placebo
placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-05175157
200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
Placebo
placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal spirometry at screening (FEV1 and FVC (Forced Vital Capacity)at least 80% predicted).
* Minimum of 20 inflammatory lesions on the face.
* Willing to discontinue other acne treatments prior to and during the study period through follow-up.
Exclusion Criteria
* Subjects unwilling to comply with lifestyle guidelines, commit to study visits, and perform study procedures.
* History of dry eye or other known disease that affects the sclera or cornea.
* History of pulmonary disease or inability to adequately perform testing.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1731019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.